论文部分内容阅读
目的 :比较欧必亭 (Tropisetron)与不同剂量地塞米松 (DXM )联用预防非铂类药物化疗所致恶心、呕吐的疗效与不良反应。方法 :采用临床随机对照方法 ,将 75例接受联合化疗的患者随机分成A、B、C三组 ,A组用欧必亭和 10mgDXM ,B组用欧必亭和 5mgDXM ,C组单用欧必亭 ,观察化疗后 2 4小时 (急性 )及 7日 (延迟性 )恶心、呕吐和不良反应发生的情况。结果 :A组、B组控制急性及延迟性恶心、呕吐疗效明显好于C组 ,而A组与B组之间结果无显著差异。结论 :欧必亭联合不同剂量DXM均能有效控制非铂类药物化疗所致的恶心、呕吐反应 ,且 10mgDXM并不比 5mgDXM有优势 ,在非淋巴系统疾病治疗中 ,DXM剂量以 5mg为宜
Objective: To compare the efficacy and side effects of Tropisetron with different dosages of dexamethasone (DXM) in preventing nausea and vomiting induced by chemotherapy of non-platinum drugs. Methods: A total of 75 patients undergoing combined chemotherapy were randomly divided into three groups: A, B and C, A and Ebipine and 10mgDXM respectively. 4 hours (acute) and 7 (delayed) nausea, vomiting and adverse reactions occurred. Results: The efficacy of acute and delayed nausea and vomiting in group A and group B was significantly better than that in group C, while there was no significant difference between group A and group B. CONCLUSION: All the doses of DXB combined with different doses of DXM can effectively control the nausea and vomiting induced by non-platinum drug chemotherapy, and 10mgDXM has no advantage over 5mgDXM. In the treatment of non-lymphatic system diseases, the dosage of DXM should be 5mg